Our Pipeline

Precision medicines for debilitating disorders with a high unmet need
Invea has identified and prioritized a pipeline of three candidates impacting the GBA for the treatment of GI and hepatobiliary disorders. Our discovery pipeline has more than 20 programs at various stages of validation.


INVA8001 is a first-in-class, oral, highly selective inhibitor of chymase impacting inflammation, tissue remodeling, and fibrosis, with proven human safety, for the treatment of Eosinophilic Gastritis/Duodenitis (EG/EoD), Eosinophilic Esophagitis (EoE), and Primary Sclerosing/Biliary Cholangitis.


INVA8002 is a novel orally delivered colon-targeted formulation of a small molecule inhibitor of a 5-HT3 receptor for the treatment of moderate to severe Ulcerative Colitis (UC), a common form of Inflammatory Bowel Disease (IBD).


INVA8003 is a first-in-class pan- inflammasome inhibitor targeting ASC protein oligomerization, which disrupts the inflammasome assembly of NLR/Ps with a broad anti-inflammatory impact and potential applications across a wide range of inflammatory GI disorders.